Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 32

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 32
---
 and limit our present and future
activities. Ultimately, we or a licensee could be prevented from commercializing a product or be forced to cease some aspect of our business
operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. 

In
addition to possible infringement claims against us, we may become a party to other patent litigation and other proceedings, including
interference, derivation, re-examination, or other post-grant proceedings declared or granted by the USPTO, and similar proceedings in
foreign countries, regarding intellectual property rights with respect to our current or future products.

There
is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries generally. To date, no litigation asserting infringement claims has ever been brought against us. If a third-party claims
that we infringe its intellectual property rights, we may face a number of issues, including:

    ●
    infringement
    and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert
    our management’s attention from our core business;

    ●
    substantial
    damages for infringement, which we may have to pay if a court decides that the product or technology at issue infringes or violates
    the third party’s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages
    and the patent owner’s attorneys’ fees;

    ●
    a
    court prohibiting us from selling or licensing the product or using the technology unless the third party licenses its intellectual
    property rights to us, which it is not required to do;

49

    ●
    if
    a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual
    property rights for our products or technologies; and

    ●
    redesigning
    our products or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and
    time.

Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could harm our ability
to raise additional funds or otherwise adversely affect our business, financial condition, operating results, and prospects.

Because
we rely on certain third